<section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="kZ_qa s_aA s_aU s_bh s_ay"><div class="kZ_IN s_d8"><a data-test-id="logo" title="Home" class="al_e5 r_Z r_ah" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="al_hR r_Z r_ae"><svg class="al_gx al_fQ al_hN"><use xlink:href="#logo"></use></svg></span></a></div><header class="rS_FM r_Z r_2 r_9 r_ah"><div class="vx_g r_Z r_2 r_9 s_d6 cu_nZ" data-test-id="quick-links"><div class="vx_Wr r_Z r_1 r_ab r_ak s_cH s_b2"><div class="vx_UW s_aR s_av s_ba"><div class="yj_iv" data-test-id="themes-list"><ul class="yj_mY r_Z"><li class="yj_mZ r_Z r_1 s_dW"><a data-test-id="theme-links-item" class="J_eB r_0 r_1 r_6 J_ga J_fx bb_jE bb_jT bb_ka O_G" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="yj_YZ iF_sX">Transcripts</span></span></a></li><li class="yj_mZ r_Z r_1 s_dW"><a data-test-id="theme-links-item" class="J_eB r_0 r_1 r_6 J_ga J_fx bb_jE bb_jT bb_ka O_G" href="/market-outlook/global-investing/analysis/canada?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Acanada%7Cfirst_level_url%3Aarticle"><span class=""><span class="yj_YZ iF_sX">Canada</span></span></a></li></ul></div></div></div><div class="vx_Wq r_Z r_1 r_9"></div></div><div class="nd_iW r_Z r_9"><h1 class="nd_ez s_d6 bb_jM bb_j4 bb_ka bb_kX bb_lf bb_lk" data-test-id="post-title">Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q2 2020 Results - Earnings Call Transcript</h1></div><div class="mb-18 flex justify-between text-medium-2-r md:mb-16 rS_RW r_Z r_1" data-test-id="post-page-meta"><div><span class="nd_Lk nd_gW q_W" data-test-id="post-date">Aug. 09, 2020 7:24 AM ET</span><span class="nd_gW q_W" data-test-id="post-primary-tickers"><a class="vy_Ws" href="/symbol/ACHV?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AACHV">Achieve Life Sciences, Inc. (ACHV)</a></span><span class="nd_KU q_Y"><a class="nd_G bb_jF bb_jU bb_j9" data-test-id="post-comments-count" href="#comments" id="commentsPianoElement">3 Comments</a></span></div></div></header><div class="tA_Od r_Z r_2 r_9 s_d6" data-test-id="author-brief"><div class="tA_Z r_Z"><a class="tA_K9 st_K9" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcset="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"></div></a><div class="tA_Oe r_Z r_6 r_ah s_cG"><a class="tA_K9 st_K9 tA_Ja bb_jG bb_jU bb_ka s_dS st_Ja" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="tA_q6 r_Z r_ab"><div class="rG_RF bb_jE bb_jT bb_j9 tA_Oc q_W bb_jE bb_jT bb_j9">141.03K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="lc_IR" role="none"><button data-state-text="Following" class="J_eB r_0 r_1 r_6 J_fQ J_fA bb_jF bb_jV bb_ka jp_FS s_at s_bx s_aU s_bh px_Hc r_am tA_wi s_ct aX_jo" data-test-id="follow-button" type="button"><span class=""><span class="jp_FU r_Z r_6" data-state-placeholder="Following"><span class="jp_FV">Follow</span></span></span></button></div></div><div class="wx_XY s_d0"><button class="J_eB r_0 r_1 r_6 J_fQ J_fA bb_jF bb_jV bb_ka yv_eB r_0 r_1" data-test-id="play-button" type="button"><span class=""><svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="yv_C7" data-test-id="play-button-play-svg"><path d="M0 16V0l16 8-16 8z" fill="currentColor"></path></svg><span class="yv_pj">Play Earnings Call</span></span></button></div><div><div class="paywall-full-content jc_f r_Z" data-test-id="article-content"><div class="jc_me r_ak"><div class="jc_is jc_EZ" data-test-id="content-container"><p>Achieve Life Sciences, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/ACHV?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Achieve Life Sciences, Inc.">ACHV</a></span>) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET</p> <p><strong>Company Participants</strong></p> <p>Jaime Xinos - Executive Vice President of Commercial</p> <p>Richard Stewart - Chief Executive Officer</p> <p>Cindy Jacobs - Executive Vice President &amp; Chief Medical Officer</p> <p>John Bencich - Chief Financial Officer &amp; Chief Operating Officer</p> <p><strong>Conference Call Participants</strong></p> <p>Michael Higgins - Ladenburg Thalmann</p> <p>John Vandermosten - Zacks</p> <p><strong>Operator</strong></p> <p>Ladies and gentlemen, thank you for standing by, and welcome to the Achieve Life Sciences Second Quarter 2020 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]</p> <p>I would know like to hand the conference over your first speaker for today, Ms. Jaime Xinos, Executive Vice President of Commercial at Achieve. Thank you. Please go ahead.</p> <p><strong>Jaime Xinos</strong></p> <p>Thank you, and thanks, everyone, for joining us. On the call today from Achieve, we have Rick Stewart, Chief Executive Officer; Dr. Cindy Jacobs, Chief Medical Officer; Dr. Anthony Clarke, Chief Scientific Officer; and John Bencich, Chief Financial and Operating Officer.</p> <p>I'd like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions, and actual results may vary materially from those projected. Please refer to Achieve's documents filed with the SEC concerning factors that could affect the company, copies of which are available on our website.</p> <p>I will now turn the call over to Rick.</p> <p><strong>Richard Stewart</strong></p> <p class="iW_EQ">Thank you, Jamie. On today's call, we will review the second quarter highlights. Firstly, the exciting top line data from the New Zealand RAUORA Phase 3 clinical trial, led by Dr. Natalie Walker. Secondly, Dr. Cindy Jacobs will review the continuing momentum of initiating the Phase 3 ORCA-2 trial in the U.S. later this year. And thirdly, John<span class="paywall-full-content invisible"> Bencich will review our financial results, plus the strengthening of our balance sheet, facilitating the start of the ORCA-2 trial.</span></p> <p class="paywall-full-content invisible">At the end of June, we announced the successful top line results from the investigator-led Phase 3 non-inferiority<span class="paywall-full-content no-summary-bullets invisible"> RAUORA trial, comparing cytisinicline to Chantix in the Maori or indigenous people of New Zealand. Our congratulations to Dr. Natalie Walker of the University of Auckland for conducting this landmark trial. The RAUORA trial evaluated the efficacy, safety, and cost effectiveness of cytisinicline compared to Chantix, or the smoking cessation aid. In total, the study randomized 679 subjects. As a non-inferiority trial, it was designed to demonstrate whether cytisinicline was at least as good as Chantix for efficacy and safety. In fact, it showed that cytisinicline efficacy was similar to Chantix, and that cytisinicline had a superior safety profile.</span></p> <p class="paywall-full-content invisible no-summary-bullets">RAUORA compared cytisinicline, administered on a modified schedule over 25 days of downward dosing titration, followed by twice daily dosing for a total of 12 weeks against Chantix, which is administered on an expanded dosing schedule of seven days of upward titration, followed by twice daily dosing for a total of 12 weeks. The primary endpoint was a comparison of biochemically confirmed, continuous abstinence rates at six months.</p> <p class="paywall-full-content invisible no-summary-bullets">The trial successfully achieved the primary endpoint, for showing that cytisinicline plus behavioral support was at least as effective as Chantix plus behavioral support at six months. In addition, the trial showed that cytisinicline resulted in significantly fewer reported adverse events when compared to Chantix. The positive top line results of the RAUORA Phase 3 trial, which is the first direct head-to-head comparative study between cytisinicline and a Chantix, provides additional evidence that cytisinicline is at least as effective as Chantix, while offering improved tolerability. We're excited about this outcome that further strengthens the potential for cytisinicline to help smokers quit.</p> <p class="paywall-full-content invisible no-summary-bullets">Importantly, these benefits were achieved using only the currently marketed 1.5 milligram dose of cytisinicline and the downward titration schedule. The dosing duration was modified to 12 weeks in order to match the Chantix dosing schedule. Our upcoming U.S. cytisinicline Phase 3 clinical trials will use the higher three-milligram dose at a simplified three times daily dosing schedule. Based on the results of the ORCA-1 Phase 2/B trial, we're optimistic that this simplified dosing schedule, in combination with a three-milligram dose, will be easier for subjects and potentially result in better smoking cessation rates than what was observed in the RAUORA trial.</p> <p class="paywall-full-content invisible no-summary-bullets">The final RAUORA trial results have been submitted by Dr. Matthew Walker, the RAUORA primary investigator, for presentation at the Society For Research on Nicotine and Tobacco European Annual Meeting, to be held this September. We look forward to sharing additional details on the RAUORA trial results when presented.</p> <p class="paywall-full-content invisible no-summary-bullets">Turning to the upcoming ORCA-2 double blind placebo-controlled Phase 3 trial. Preparations are underway for the trial commencement in the fourth quarter. These preparations include careful risk management assessments for any potential impact of the COVID-19 pandemic. Our continuous risk assessment dialogue with clinical trial sites and our CRO still indicates that initiation of the ORCA-2 trial in the fourth quarter of this year remains feasible. The health and safety of our trial participants, healthcare providers, and employees will continue to be our number one priority. We continue to monitor the crisis in real time, taking advice and precautions to minimize risk to all involved.</p> <p class="paywall-full-content invisible no-summary-bullets">I'll now turn the call over to Cindy to review the ORCA-2 trial design and provide the regulatory updates.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Cindy Jacobs</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, Rick. The ORCA-2 safety trial builds on our experience from the successful ORCA-1 trial. Valuable lessons were learned, which have been integrated into the trial design, along with specific requirements requested by FDA. We have consulted frequently with our key opinion leaders, who have given us the benefits of their wisdom and we are now finalizing preparations to commence the trials in the fourth quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">ORCA-2 is a multi-center, double blind, randomized, placebo-controlled Phase 3 study that will randomize 750 adults, who are daily cigarettes smokers, intending to quit smoking, and are willing to set a quit date within seven days of starting treatments. Participants will be randomly assigned with equal probability to one of three arms. Arm A will receive 12 weeks placebo treatment, Arm B will receive six weeks of cytisinicline, and then be switched to placebo for the latter six weeks, and arm C will receive 12 weeks of cytisinicline.</p> <p class="paywall-full-content invisible no-summary-bullets">There will be 250 subjects in each arm, receiving either placebo or cytisinicline three times a day for the 12-week study treatment period, and then followed monthly out to week 24 for a six-month evaluation. All 750 subjects will receive behavioral support during the entire 24 weeks. Similar to ORCA-1, each smoker will start study drug treatment the day after being randomized, and will have their quit date set within the following five to seven days, or at least by the end of the first week of treatment. Starting after their quit date, at least two of treatments, assessments for smoking abstinence will begin by weekly self-reporting of abstinence or not, with biochemical verification of abstinence by exhaled carbon monoxide levels. These weekly assessments occur through the 12 weeks of blinded study treatment, then monthly follow-up assessments will occur for smoking abstinence at week 16, 20, and finally, week 24.</p> <p class="paywall-full-content invisible no-summary-bullets">The ORA-2 study has two independent primary endpoints that will be evaluated. The primary endpoint outcomes will evaluate the rate of smoking abstinence of cytisinicline treatment at both the end of six weeks and 12 weeks treatment periods compared to the placebo treatment. For both primary and point comparisons, smoking abstinence will be defined as continuous abstinence during the last four weeks of treatment. That means for the six-week treatment period, successful quitters must have smoked zero cigarettes with weekly CO biochemical verification at weeks three, four, five, and six assessments. For the 12-week treatment period, successful quitters must have smoked zero cigarettes with weekly CO biochemical verification at weeks nine, 10, 11 and 12 assessments.</p> <p class="paywall-full-content invisible no-summary-bullets">The secondary endpoint outcomes will evaluate for continued smoking abstinence from the end of six weeks cytisinicline treatment to week 24, and from the end of 12 weeks cytisinicline treatment to week 24, separately and compared to placebo treatment within these same timeframes. An additional secondary endpoint outcome will look for a reduction in risk of relapse from weeks six to 24 in subjects receiving cytisinicline for six weeks versus 12 weeks. The sample size for this study is specified as 250 subjects per arm. This assumes a difference of 12% benefit for cytisinicline over placebo, with 96% power.</p> <p class="paywall-full-content invisible no-summary-bullets">ORCA-2 will enroll at approximately 15 clinical sites across the U.S. Each site will have specific COVID-19 protection operating procedures in place. We are preparing for potential restricted site interactions if a site needs to be quarantine, with remote testing or monitoring and procedures for missing data, per FDA guidelines, if a subject becomes infected with COVID-19 and cannot be evaluated.</p> <p class="paywall-full-content invisible no-summary-bullets">From a regulatory update and perspective, we have now completed all required non-clinical submissions to initiate our Phase 3 program. This has included submitting to FDA all the non-clinical data required to support the six and 12 weeks of cytisinicline treatment in the Phase 3 trial. In addition, we have submitted the final protocol for the ORCA-2 Phase 3 trial. As discussed last fall, we reviewed the Phase 3 protocols and the statistical plans with the FDA in a Type B meeting in November of 2019, and have incorporated FDA input from that meeting into that final protocol. We are now proceeding with the final operational planning and logistics to initiate the Phase 3 in the fourth quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">So in summary, we intend to initiate ORCA-2 in the fourth quarter of this year, and this trial will address three key factors, the evaluation of the higher three-milligram dose of cytisinicline for both six and 12 weeks of treatment, the simplification of the dosing schedule given only three times daily, leading to ease of use, regardless of treatment duration, and the extension of the treatment duration of six and 12 weeks to potentially increase quit rates and yield more durable efficacy results. The extension of the dosing period in the Phase 3 trial has significant benefits. It will allow us to measure the primary endpoint of four weeks of continuous abstinence, while subjects are still receiving cytisinicline treatment. This wasn't possible with a 25-day treatment period in the ORCA-1 trial. As documented in the literature, measuring efficacy while subjects are and remained on treatment typically results in higher quit rates.</p> <p class="paywall-full-content invisible no-summary-bullets">I will now turn the call over to John to discuss recent financing activities and our second quarter results.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>John Bencich</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, Cindy. I'd like to first provide an update on our recent financings and cash position, and then review our second quarter financials. Post the end of the second quarter, we have announced two public equity financings, totaling $13.5 million in gross proceeds. Both of these transactions were common stock only that were priced at stepped up valuations from the previous. Last month, we announced the closing of a $6 million registered direct financing. The financing was completed at no discount to the previous closing share price. The financing provided net cash of approximately $5.5 million after deducting placement agent commissions and operating expenses.</p> <p class="paywall-full-content invisible no-summary-bullets">This week, we announced the pricing of an underwritten public offering with gross proceeds of approximately $7.5 million. This was also a common stock only offering that included the full exercise of the underwriters overallotment option, and will provide estimated net proceeds of approximately $6.8 million after deducting commissions and offering expenses. In addition, subsequent to the end of the second quarter, we have also seen outstanding warrants exercised that have provided an additional $2.3 million in cash proceeds.</p> <p class="paywall-full-content invisible no-summary-bullets">In total, we have received approximately $2.9 million in proceeds for warrant exercises since the start of the second quarter. The additional capital will help to maintain momentum on cytisinicline development and set us up with a strong balance sheet going into the second half of the year, as we initiate the ORCA-2 Phase 3 trial. As of June 30, 2020, the Company's cash, cash equivalents, short-term investments, and restricted cash were $12.2 million. On a pro forma basis, including the July and August financings, as well as warrant exercises, we'll be starting the third quarter of 2020 with approximately $26.7 million of cash on hand.</p> <p class="paywall-full-content invisible no-summary-bullets">Turning to our statement of operations, the Company incurred a net loss of $2.9 million for the quarter ended June 30, 2020, as compared to a net loss of $3.6 million for the quarter ended June 30, 2019. Net loss for the six months ended June 30, 2020 decreased to $6.3 million, compared to $9.6 million for the six months ended June 30, 2019. As noted previously, we expect our quarterly operating expenses to remain lower in advance of initiating the Phase 3 trial.</p> <p class="paywall-full-content invisible no-summary-bullets">That concludes the summary of our second quarter financial results. I would like to now turn the call back over to Rick.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Richard Stewart</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, John. The second quarter highlighted the true potential of cytisinicline as a future leader in the smoking cessation market, with a result - with the release of successful top line results from the RAUORA Phase 3 trial, comparing cytisinicline and the current market leader, Chantix. Additionally, we continue to make excellent progress, preparing for the commencement of the ORCA-2, 750- subject, placebo-controlled Phase 3 trial. And of course, we took the opportunity to add additional capital during the quarter to further reinforce our balance sheet.</p> <p class="paywall-full-content invisible no-summary-bullets">The RAUORA trial results are a landmark because this is the first direct head-to-head comparison of cytisinicline efficacy and safety compared to the current market leader, Chantix, which reported 2019 global sales, just shy of $1.1 billion. We're pleased that cytisinicline showed its potential to compete strongly with Chantix, and clinical data continues to indicate a potential best-in-class profile for cytisinicline for smoking cessation. We are well prepared to start the upcoming Phase 3, with FDA requirements fully met. The non-clinical data required by FDA to commence the ORCA-2 Phase 3 trial has now been submitted for FDA review. Preparations for the start of the Phase 3 trial progress, with the aid of leading KOLs in the field, and we remain optimistic that the first Phase 3 trial will commence in the fourth quarter of 2020, COVID-19 permitting.</p> <p class="paywall-full-content invisible no-summary-bullets">Finally, I'd like to briefly discuss the impact of COVID-19, specifically on smokers, and why we believe cytisinicline will have a key role to play in aiding smokers to quit in the future. Advice from the regulatory agencies, such as the CDC and WHO, has never been stronger or more vital about quitting smoking. The impact of COVID-19 in individuals with pre-existing conditions, such as pulmonary, cardiovascular, and other smoking-related diseases, has amplified the urgency to quit smoking now. There are two key COVID-19 implications for smokers. Firstly, the impact of cigarette smoking on lung health is incredibly damaging, and believed to lead to more susceptibility to the COVID-19 virus and more severe symptoms. And secondly, it appears that smoking rates are on the rise, as a result of changing social dynamics, reports of vaping-related lung disease, and the banning of flavored vape products. There has never been a more critical time for smokers to quit for good, and we believe cytisinicline can play an important role in helping them do so.</p> <p class="paywall-full-content invisible no-summary-bullets">Thank you again for joining us today. That concludes our prepared remarks, and we will now open the line for questions. Please open the line.</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] First question is from the line of Michael Higgins of Ladenburg Thalmann. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Michael Higgins</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi, guys. Thanks for taking the questions. Congratulations on the continued progress. We seem to be going along as planned here, despite the challenges of the year. Question for you as we look ahead to SRHE confidence or SRHEE, that's being posted online this year. How should we look for KOLs and ourselves to learn about prior results, given the online format conference? Are expecting a webinar specific to these results to be provided for the Q&amp;A portion? How should we plan for this? Thanks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Stewart</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I'll have that one over to Cindy.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Cindy Jacobs</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, we know the SRNT-E meeting will be virtual. So we expect that Natalie will be narrating her slides in detail for that presentation. I think we have discussed whether we would have a webinar afterwards. And it's interesting that you asked that question because that would be then something we could do afterwards within that month time period, very similar to what we did with the ORCA-1 results.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Michael Higgins</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I see. So kind of an analyst day, post the SRNT-E presentation?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Cindy Jacobs</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. We'd have to work that in with Natalie's schedule as well. Obviously, it's a little bit more problematic when you're looking at the New Zealand. But yes, we've talked about how sadly some of us might have to be doing this in the middle of the night.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Michael Higgins</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">All right, well, obviously, we're hoping for during the day for ourselves.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Cindy Jacobs</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, the East Coast definitely. I think West Coast people that will be in the middle of the night, my guess is.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Michael Higgins</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Understood. I feel your pain. Any progress for us on the EVFA [ph] study that you can relate to us? Didn't hear a lot on that in your prepared remarks, but obviously, that's something we're all following as well. Thanks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] Your next question is from the line of John Vandermosten of Zacks. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">John Vandermosten</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Good afternoon, guys. And thanks for taking my questions. And also, congratulations on the capital raise. Great to see that almost $30 million balance you have there. And if I remember correctly, I think that it was allocated about $15 million for the ORCA-2, and then another $15 million for the second, if I if I'm remembering correctly. But can you just give me a sense of how much more capital you'll need to finish off both of the trials, given your current status on the cash side of things?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Stewart</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">John, do you want to do that one?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">John Bencich</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. Absolutely. Thanks for the question, John. And yes, your memory is correct. The Phase 3 trial is approximately a $15 million study, which I think as we described on the call, having close to $27 million on the balance sheet puts is in a great position to execute on that trial. And the second Phase 3 will be approximately the same capital requirements.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">John Vandermosten</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, great. So, you're pretty close to having what you need to finish this off. That's great news. Let's - so just an update on when we might see a generic competitor for Chantix. I think we might have discussed this last time, and I think there was just a little uncertainty on how much the patent protection was providing for them. What is the latest view on that in terms of a Chantix competitor or Chantix generic coming out?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Stewart</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, I'll take that one. What we're looking at the moment is really the expiry of the more important patent looks like it's around about May, June of 2022. So we're not actually - plus there's going to be additional protection from a pediatric extension. So we're anticipating seeing some generic competition, probably early part of 2023.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">John Vandermosten</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, got it. Thanks for that. That's great. That's great. And then you mentioned this, Rick, just a little bit about changes in smoking behavior. I mean, has there been any observations of how that has changed as the Coronavirus has started? I mean, people have picked up a lot of different habits. I think people have been drinking more alcohol. But I don't know about trends for smoking. I know there's been a big health trend as well. But have you seen any data out there on actual smoking and how that might have changed since March of this year to present?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Stewart</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, it's really a shift from vaping back into cigarette smoking. We've all we've always maintained that in terms of risk reduction or harm reduction, vaping is around about 95% improvement versus cigarette smoking. But I think with some of the lockdown pressures that people have experienced, plus some of the issues and concerns around the lung disease associated with vaping, we've seen people who were attempting to quit move back towards cigarette smoking. So yes, there is data out there, which is supporting the idea that it's more in that area. I mean, there are 11 million vapors right now. Roughly half of those are youth. But it's the other half who were perhaps more reformed smokers, who now seem to be moving at least back towards cigarette smoking.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">John Vandermosten</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, interesting. Interesting shifts there. And last question on the on the vaping study that you guys were working on. Any progress there? And any closer to getting that grant money for the study in that area?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Richard Stewart</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, I mean, it's a highly competitive process. And frankly, we didn't make the cuts as far as the NIH is concerned. But we continue to believe that a vaping study will add substantial value, and we're seeking alternative funding sources. So it's an area that we're significantly interested in. Our KOLs are interested in pursuing that. But our capital is focused on the Phase 3 clinical trials. So we're looking at alternative sources of grant funding for that vaping study.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">John Vandermosten</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, great. Thank you. I'll get back in queue.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">I am showing no further questions. At this time, I would like to turn the conference back to Mr. Rick Stewart, CEO of Achieve.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Richard Stewart</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, thank you again for joining the call and your continuing interest in supporting Achieve. And we look forward to talking to you again with our third quarter results. Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Ladies and gentlemen, this concludes today's conference. Thank you all for participating. You may now disconnect.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="jc_E0" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->ACHV<!-- --> <a class="J_eB r_0 r_1 r_6 O_G O_gz" href="/symbol/ACHV"><span class="">analysis and news</span></a></li><li class="jc_E0" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="J_eB r_0 r_1 r_6 O_G O_gz" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nb_T r_Z r_9 aX_jo paywall-full-content" data-test-id="post-footer"><span class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8"><button class="ur_CG rz_Rn r_Z r_1 ur_hX" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="ur_fw"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="ur_hG">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="custom-share-button" type="button"><span class="truncate"><span class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="nc_fw"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="nc_hG s_cG">Share</span></span></span></button><button aria-expanded="false" aria-label="Print options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="print-dropdown" type="button"><span class="truncate"><span class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8"><svg viewBox="0 0 14 13" xmlns="http://www.w3.org/2000/svg" class="nc_fw"><path d="M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z"></path></svg><span class="nc_hG s_cG">Print</span></span></span></button><a class="nc_G nc_Li r_Z r_1 s_aA s_bE s_aL s_a8 nb_Le" data-test-id="comment-button" href="/article/4366633-achieve-life-sciences-inc-achv-ceo-richard-stewart-on-q2-2020-results-earnings-call#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="nc_fw nb_Lh"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="nc_hG s_cG">Comment<!-- -->s (3)</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="recommended-for-you-card-body"><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4637656-sell-everything">Sell Everything</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="lk_a r_Z r_1 r_6" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lk_oX lk_gj"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643307-trade-alert-buy-the-dip-on-this-16-percent-yield-pdi">Trade Alert, Buy The Dip On This 16% Yield: PDI</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Colorado Wealth Management Fund profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/014/527/192/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4644122-disaster-strikes-mortgage-reits-under-siege">Disaster Strikes: Mortgage REITs Under Siege</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Colorado Wealth Management Fund</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Mott Capital Management profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/026/750/043/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643839-the-new-bull-market-is-over">The New Bull Market Is Over</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Mott Capital Management</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Bohdan Kucheriavyi profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/040/909/655/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4644078-amazon-q3-time-to-sell-rating-downgrade">Amazon Q3: Time To Sell (Rating Downgrade)</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Bohdan Kucheriavyi</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Quad 7 Capital profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/003/949/741/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643879-medical-properties-trust-is-fighting-for-its-life">Medical Properties Trust Is Fighting For Its Life</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Quad 7 Capital</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643755-is-the-bull-market-over">Is The Bull Market Over?</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="lk_a r_Z r_1 r_6" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lk_oX lk_gj"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4643534-5-reits-with-no-near-term-debt-maturities-and-virtually-no-floating-rate-debt">5 REITs With No Near-Term Debt Maturities And Virtually No Floating Rate Debt</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Cress profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/050/113/560/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4641618-seeking-alpha-vs-motley-fool">Seek Alpha: Don't Be A Fool</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Steven Cress</span></footer></div></div></div></article><article class="gI_gW fD_gW r_Z s_aL s_a8 kO_Is s_ay s_bC kO_Is s_ay s_bC kO_Iw kO_Iw gI_zW" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Samuel Smith profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/047/771/937/big_pic.png" width="36"></div></div><div><div class="iH_vz r_Z iH_Ek"><div class="iH_Ep"><h3 class="iH_ez s_ao r_ak iH_x1 bb_jG bb_jU bb_ka iH_Em s_dS"><a data-test-id="post-list-item-title" class="iH_G" href="/article/4634680-buffett-and-munger-say-invest-100000-to-build-a-passive-income-snowball">Buffett And Munger Say Invest $100,000 To Build A Passive Income Snowball</a></h3><footer class="kA_T bb_jE bb_jU bb_j9" data-test-id="post-footer"><span class="oB_Ja" data-test-id="post-list-author">Samuel Smith</span></footer></div></div></div></article></div></div></div></div></section><div class="rK_RL" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="rK_qa"><div class="paywall-full-content"><div class="oY_N0 r_Z r_1 s_eb" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="oY_ez r_Z r_1 bb_jK bb_j0 bb_j9 s_c8 s_dO" data-test-id="comments-counter">Comments<!-- --> <!-- -->(<!-- -->3<!-- -->)</h4><div><button aria-expanded="false" aria-label="Sort By" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="sort-comments-button" type="button"><span class="truncate"><span class="rF_RC r_Z r_1"><span class="rF_RD s_dh ba_jy bb_jF bb_jV bb_j9">Newest</span><div class="sS_SX rF_fw r_Z r_1"><span class="rF_RE"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 rC_Ru s_cC" data-test-id="dropdown" type="button"><span class="truncate"><span class="rC_os r_Z r_1 r_6"><svg class="rC_Rt"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="uE_g qH_g s_d8 aX_jo" data-test-id="add-comment-form"><div class="uE_Qi qH_Qi r_Z"><div class="uE_Fc s_dn"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="uE_Qj qH_Qj"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 uE_Qk qH_Qk s_d6 s_av s_aR s_be s_bz ua_Vh" contenteditable="true" data-test-id="add-comment-input" placeholder="Add your comment..." role="textbox" tabindex="0"></div><div class="uE_xN qH_xN r_Z r_1 r_7"><button disabled="" class="J_eB r_0 r_1 r_6 J_fQ J_fA bb_jF bb_jV bb_ka uE_Qm qH_Qm s_cM" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div><div class="" data-test-id="comment"><div class="yJ_Le qH_Le r_Z s_ay s_bC"><div class="yJ_Fc s_dn" data-test-id="comment-user-pic"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="pat45 profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static2.seekingalpha.com/images/users_profile/000/760/650/small_pic.png?t=7da0c90368" srcset="https://static2.seekingalpha.com/images/users_profile/000/760/650/big_pic.png?t=2d3db05f9f 2x, https://static2.seekingalpha.com/images/users_profile/000/760/650/big_pic.png?t=2d3db05f9f 3x" width="36"></div></div><div class="yJ_vz r_ak"><div class="yJ_I r_Z r_ah s_d4"><div class="yJ_KJ r_Z r_1 r_9 s_dW"><a class="yJ_Fd" data-test-id="comment-author-nick" rel="" href="/user/760650">pat45</a><div class="AH_eI r_Z r_1 bb_jE bb_jT bb_j9"><span data-test-id="comment-date"><span class="AH_wP">17 Sep. 2020, 11:25 AM</span></span><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 AH_rd" data-test-id="dropdown" type="button"><span class="truncate"><span class="AH_JP r_Z s_cM"><svg class="AH_Jg"><use xlink:href="#info"></use></svg></span></span></button></div></div><div class="yJ_Zt r_Z r_ah s_b0 bb_jE bb_jT bb_j9"><div class="yJ_Zu s_au"><div class="BV_a q_V"><a class="" href="/premium?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Acomments%7Csection_asset%3Abadge%7Cbutton%3APremium"><span class="gj_rl r_0 r_1 r_6 gj_oX s_aq s_bu s_aO s_bb bb_jC bb_jR bb_ka gj_nA BV_rl s_dh s_dW s_ar s_bv s_aO s_bb" data-test-id="status-badge"><span>Premium</span></span></a></div></div><div class="yJ_Zv s_au r_Z r_9"><div class="yJ_ZC r_Z r_1"><a class="yJ_F5" data-test-id="comment-count" href="/user/760650#comments">Comments (9.56K)</a></div></div></div></div><div class="yJ_f s_d4" data-test-id="comment-content">Cytisinicline demonstrated quit rates at least as effective as varenicline<p class="txt-sep"></p>Participants on cytisinicline experienced significantly fewer side effects than those on varenicline<p class="txt-sep"></p>SEATTLE and VANCOUVER, BC, June 29, 2020 /CNW/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the successful topline results from the New Zealand RAUORA Phase 3 non-inferiority clinical trial comparing cytisinicline to varenicline (Chantix) in Mori (indigenous New Zealanders) and whnau (family) of Mori. The study was led by Dr. Natalie Walker, Associate Professor at the University of Auckland, and was funded by the Health Research Council of New Zealand.<p class="txt-sep"></p>will start Orca-2 (p3 in USA) around september</div><div class="AJ_OF r_Z r_3"><button aria-label="Reply to pat45" class="J_eB r_0 r_1 r_6 AJ_0T s_dB" data-test-id="reply-button" type="button"><span class=""><svg viewBox="0 0 18 13" xmlns="http://www.w3.org/2000/svg" class="AJ_0U"><path d="m11.33 13-.01-4.16h-.11c-.08 0-.2 0-.35-.02a14.09 14.09 0 0 1-5.12-1.34 9.78 9.78 0 0 1-3.88-3.21 9.68 9.68 0 0 1-.92-1.68C.46 1.59 0 0 0 0l2.11 1.72c2.1 1.71 4.86 2.39 9.21 2.46V0L18 6.5 11.33 13zm1.5-5.67v2.1l3.02-2.93-3.02-2.95v2.12h-1.5c-2.87 0-5.29-.38-7.25-1.12a8.5 8.5 0 0 0 2.31 1.58 12.87 12.87 0 0 0 4.86 1.2h1.58z"></path></svg><span class="AJ_0V s_cC">Reply</span></span></button><button aria-label="Like comment" class="ur_CG AJ_0S r_Z r_3 ur_Vs" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="ur_fw"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="ur_hG">Like</span></button></div></div></div></div><div class="" data-test-id="comment"><div class="yJ_Le qH_Le r_Z s_ay s_bC"><div class="yJ_Fc s_dn" data-test-id="comment-user-pic"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="pat45 profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static2.seekingalpha.com/images/users_profile/000/760/650/small_pic.png?t=7da0c90368" srcset="https://static2.seekingalpha.com/images/users_profile/000/760/650/big_pic.png?t=2d3db05f9f 2x, https://static2.seekingalpha.com/images/users_profile/000/760/650/big_pic.png?t=2d3db05f9f 3x" width="36"></div></div><div class="yJ_vz r_ak"><div class="yJ_I r_Z r_ah s_d4"><div class="yJ_KJ r_Z r_1 r_9 s_dW"><a class="yJ_Fd" data-test-id="comment-author-nick" rel="" href="/user/760650">pat45</a><div class="AH_eI r_Z r_1 bb_jE bb_jT bb_j9"><span data-test-id="comment-date"><span class="AH_wP">17 Sep. 2020, 8:17 AM</span></span><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 AH_rd" data-test-id="dropdown" type="button"><span class="truncate"><span class="AH_JP r_Z s_cM"><svg class="AH_Jg"><use xlink:href="#info"></use></svg></span></span></button></div></div><div class="yJ_Zt r_Z r_ah s_b0 bb_jE bb_jT bb_j9"><div class="yJ_Zu s_au"><div class="BV_a q_V"><a class="" href="/premium?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Acomments%7Csection_asset%3Abadge%7Cbutton%3APremium"><span class="gj_rl r_0 r_1 r_6 gj_oX s_aq s_bu s_aO s_bb bb_jC bb_jR bb_ka gj_nA BV_rl s_dh s_dW s_ar s_bv s_aO s_bb" data-test-id="status-badge"><span>Premium</span></span></a></div></div><div class="yJ_Zv s_au r_Z r_9"><div class="yJ_ZC r_Z r_1"><a class="yJ_F5" data-test-id="comment-count" href="/user/760650#comments">Comments (9.56K)</a></div></div></div></div><div class="yJ_f s_d4" data-test-id="comment-content">ACHV has almost $9 book value in cash and very low market cap...if can get chantix like drug approved could go up 10x</div><div class="AJ_OF r_Z r_3"><button aria-label="Reply to pat45" class="J_eB r_0 r_1 r_6 AJ_0T s_dB" data-test-id="reply-button" type="button"><span class=""><svg viewBox="0 0 18 13" xmlns="http://www.w3.org/2000/svg" class="AJ_0U"><path d="m11.33 13-.01-4.16h-.11c-.08 0-.2 0-.35-.02a14.09 14.09 0 0 1-5.12-1.34 9.78 9.78 0 0 1-3.88-3.21 9.68 9.68 0 0 1-.92-1.68C.46 1.59 0 0 0 0l2.11 1.72c2.1 1.71 4.86 2.39 9.21 2.46V0L18 6.5 11.33 13zm1.5-5.67v2.1l3.02-2.93-3.02-2.95v2.12h-1.5c-2.87 0-5.29-.38-7.25-1.12a8.5 8.5 0 0 0 2.31 1.58 12.87 12.87 0 0 0 4.86 1.2h1.58z"></path></svg><span class="AJ_0V s_cC">Reply</span></span></button><button aria-label="Like comment" class="ur_CG AJ_0S r_Z r_3 ur_Vs" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="ur_fw"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="ur_hG">Like</span></button><span class="AJ_RF s_cy"><button class="J_eB r_0 r_1 r_6 tk_Tj" type="button"><span class="">(1)</span></button></span></div></div></div></div><div class="" data-test-id="comment"><div class="yJ_Le qH_Le r_Z s_ay s_bC"><div class="yJ_Fc s_dn" data-test-id="comment-user-pic"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="pat45 profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static2.seekingalpha.com/images/users_profile/000/760/650/small_pic.png?t=7da0c90368" srcset="https://static2.seekingalpha.com/images/users_profile/000/760/650/big_pic.png?t=2d3db05f9f 2x, https://static2.seekingalpha.com/images/users_profile/000/760/650/big_pic.png?t=2d3db05f9f 3x" width="36"></div></div><div class="yJ_vz r_ak"><div class="yJ_I r_Z r_ah s_d4"><div class="yJ_KJ r_Z r_1 r_9 s_dW"><a class="yJ_Fd" data-test-id="comment-author-nick" rel="" href="/user/760650">pat45</a><div class="AH_eI r_Z r_1 bb_jE bb_jT bb_j9"><span data-test-id="comment-date"><span class="AH_wP">13 Aug. 2020, 8:49 PM</span></span><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 AH_rd" data-test-id="dropdown" type="button"><span class="truncate"><span class="AH_JP r_Z s_cM"><svg class="AH_Jg"><use xlink:href="#info"></use></svg></span></span></button></div></div><div class="yJ_Zt r_Z r_ah s_b0 bb_jE bb_jT bb_j9"><div class="yJ_Zu s_au"><div class="BV_a q_V"><a class="" href="/premium?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Acomments%7Csection_asset%3Abadge%7Cbutton%3APremium"><span class="gj_rl r_0 r_1 r_6 gj_oX s_aq s_bu s_aO s_bb bb_jC bb_jR bb_ka gj_nA BV_rl s_dh s_dW s_ar s_bv s_aO s_bb" data-test-id="status-badge"><span>Premium</span></span></a></div></div><div class="yJ_Zv s_au r_Z r_9"><div class="yJ_ZC r_Z r_1"><a class="yJ_F5" data-test-id="comment-count" href="/user/760650#comments">Comments (9.56K)</a></div></div></div></div><div class="yJ_f s_d4 yJ_ZA" data-test-id="comment-content">so Orca-2 study will start in Sept??  and data out at end of year or early 2021??  Will this be the last study needed before applying to FDA ??  And how long will this type of "drug" take to get thru FDA.  I see that chantix annual sales are almost $1 billion in US and US is almost entire market</div><div class="AJ_OF r_Z r_3"><button aria-label="Reply to pat45" class="J_eB r_0 r_1 r_6 AJ_0T s_dB" data-test-id="reply-button" type="button"><span class=""><svg viewBox="0 0 18 13" xmlns="http://www.w3.org/2000/svg" class="AJ_0U"><path d="m11.33 13-.01-4.16h-.11c-.08 0-.2 0-.35-.02a14.09 14.09 0 0 1-5.12-1.34 9.78 9.78 0 0 1-3.88-3.21 9.68 9.68 0 0 1-.92-1.68C.46 1.59 0 0 0 0l2.11 1.72c2.1 1.71 4.86 2.39 9.21 2.46V0L18 6.5 11.33 13zm1.5-5.67v2.1l3.02-2.93-3.02-2.95v2.12h-1.5c-2.87 0-5.29-.38-7.25-1.12a8.5 8.5 0 0 0 2.31 1.58 12.87 12.87 0 0 0 4.86 1.2h1.58z"></path></svg><span class="AJ_0V s_cC">Reply</span></span></button><button aria-label="Like comment" class="ur_CG AJ_0S r_Z r_3 ur_Vs" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="ur_fw"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="ur_hG">Like</span></button><span class="AJ_RF s_cy"><button class="J_eB r_0 r_1 r_6 tk_Tj" type="button"><span class="">(1)</span></button></span></div></div></div></div></div><div class="wA_hG s_b5 bb_jF bb_jU bb_j9"><span>To report an error in this transcript<!-- -->, <button class="J_eB r_0 r_1 r_6 yo_Y0" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$-->